CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 270 enrolled
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02556307
NCT02556307N/ACompleted
CompareCT.gov

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Hoffmann-La Roche·observational·Posted Sep 22, 2015·Updated Feb 15, 2016

In Brief

An observational study evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 270 participants across 4 sites.

Detailed Summary

In this Slovenian, multi-center, observational study, the effectiveness of standard of care Peginterferon alfa-2a + ribavirin treatment in adult patients with chronic hepatitis C (CHC) is examined. Patients were treated for 24- or 48-weeks, as prescribed by the treating physician, followed by a 24-week follow-up period.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesSlovenia
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 22, 2015
Enrollment StartMar 1, 2009
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 10.8 years ago

Interventions

Peginterferon alfa-2adrug

Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.

Ribavirindrug

Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.